Ponatinib

(Iclusig®)

Iclusig®

Drug updated on 11/9/2023

Dosage FormTablet (oral; 10mg, 15mg, 30mg, 45mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors in adult patients.
  • For the treatment of accelerated phase (AP) or blast phase (BP) CML or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated in adult patients.
  • For the treatment of T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Ph+ ALL in adult patients.

Product Monograph / Prescribing Information

Document TitleYearSource
Iclusig (ponatinib) Prescribing Information.2022Takeda Pharmaceuticals America Inc., Lexington, MA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Utilize a response-based dosing strategy in CP-CML.2022ICLUSIG.com
Chronic myeloid leukemia, version 2.2021.2020Journal of the National Comprehensive Cancer Network
Acute lymphoblastic leukemia, version 2.2021.2020Journal of the National Comprehensive Cancer Network